{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:07:40Z","timestamp":1788433660730,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2018YFA0208902"],"award-info":[{"award-number":["2018YFA0208902"]}]},{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["NSFC No. U1604281"],"award-info":[{"award-number":["NSFC No. U1604281"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Science Foundation of China","award":["BJSFC No. 7171008"],"award-info":[{"award-number":["BJSFC No. 7171008"]}]},{"name":"National Key Scientific Instrument Special Program of China","award":["Grant No. 2011YQ03013405"],"award-info":[{"award-number":["Grant No. 2011YQ03013405"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The role of JAM3 in different tumors is controversial. The epigenetic regulation and the mechanism of JAM3 remain to be elucidated in human esophageal cancer (EC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eleven EC cell lines, 49 cases of esophageal intraepithelial neoplasia (EIN) and 760 cases of primary EC samples were employed. Methylation-specific polymerase chain reaction, immunohistochemistry, MTT, western blot and xenograft mouse models were applied in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The inverse association between RNA expression and promoter region methylation of JAM3 was found by analyzing 185 cases of EC samples extracted from the TCGA database (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). JAM3 was highly expressed in KYSE450, KYSE520, TE1 and YES2 cells, low level expressed in KYSE70 cells and unexpressed in KYSE30, KYSE150, KYSE410, KYSE510, TE13 and BIC1 cells. JAM3 was unmethylated in KYSE450, KYSE520, TE1 and YES2 cells, partial methylated in KYSE70 cells and completely methylated in KYSE30, KYSE150, KYSE410, KYSE510, TE13 and BIC1 cells. The expression of JAM3 is correlated with methylation status. The levels of JAM3 were unchanged in KYSE450, KYSE520, TE1 and YES2 cells, increased in KYSE70 cells and restored expression in KYSE30, KYSE150, KYSE410, KYSE510, TE13 and BIC1 cells after 5-aza-2\u2032-deoxycytidine treatment, suggesting that the expression of JAM3 is regulated by promoter region methylation. JAM3 was methylated in 26.5% (13\/49) of EIN and 51.1% (388\/760) of primary EC, and methylation of JAM3 was associated significantly with tumor differentiation and family history (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Methylation of JAM3 is an independent prognostic factor of poor 5-year overall survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). JAM3 suppresses cell proliferation, colony formation, migration and invasion and induces G1\/S arrest and apoptosis in EC. Further study demonstrated that JAM3 suppressed EC cells and xenograft tumor growth by inhibiting Wnt\/\u03b2-catenin signaling.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>JAM3 is frequently methylated in human EC, and the expression of JAM3 is regulated by promoter region methylation. JAM3 methylation is an early detection and prognostic marker of EC. JAM3 suppresses EC growth both in vitro and in vivo by inhibiting Wnt signaling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-022-01388-3","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T12:03:49Z","timestamp":1669982629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Epigenetic silencing of JAM3 promotes esophageal cancer development by activating Wnt signaling"],"prefix":"10.1186","volume":"14","author":[{"given":"Weili","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomo","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhou","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"issue":"3","key":"1388_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10110","key":"1388_CR2","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/S0140-6736(17)31462-9","volume":"390","author":"J Lagergren","year":"2017","unstructured":"Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet (London, England). 2017;390(10110):2383\u201396.","journal-title":"Lancet (London, England)"},{"issue":"11","key":"1388_CR3","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.3390\/cancers12113077","volume":"12","author":"S Khalafi","year":"2020","unstructured":"Khalafi S, Lockhart AC, Livingstone AS, El-Rifai W. Targeted molecular therapies in the treatment of esophageal adenocarcinoma, are we there yet? Cancers. 2020;12(11):3077.","journal-title":"Cancers"},{"key":"1388_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13148-016-0210-9","volume":"8","author":"K Ma","year":"2016","unstructured":"Ma K, Cao B, Guo M. The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma. Clin Epigenet. 2016;8:43.","journal-title":"Clin Epigenet"},{"issue":"15","key":"1388_CR5","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1158\/1078-0432.CCR-05-2858","volume":"12","author":"M Guo","year":"2006","unstructured":"Guo M, Ren J, House MG, Qi Y, Brock MV, Herman JG. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2006;12(15):4515\u201322.","journal-title":"Clin Cancer Res"},{"issue":"7498","key":"1388_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature13176","volume":"509","author":"Y Song","year":"2014","unstructured":"Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509(7498):91\u20135.","journal-title":"Nature"},{"key":"1388_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40364-019-0174-y","volume":"7","author":"M Guo","year":"2019","unstructured":"Guo M, Peng Y, Gao A, Du C, Herman JG. Epigenetic heterogeneity in cancer. Biomark Res. 2019;7:23.","journal-title":"Biomark Res"},{"issue":"1","key":"1388_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1083\/jcb.142.1.117","volume":"142","author":"I Mart\u00ecn-Padura","year":"1998","unstructured":"Mart\u00ecn-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol. 1998;142(1):117\u201327.","journal-title":"J Cell Biol"},{"issue":"2","key":"1388_CR9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4049\/jimmunol.163.2.553","volume":"163","author":"H Ozaki","year":"1999","unstructured":"Ozaki H, Ishii K, Horiuchi H, Arai H, Kawamoto T, Okawa K, et al. Cutting edge: combined treatment of TNF-alpha and IFN-gamma causes redistribution of junctional adhesion molecule in human endothelial cells. J Immunol (Baltimore, Md: 1950). 1999;163(2):553\u20137.","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"44","key":"1388_CR10","doi-asserted-by":"publisher","first-page":"34750","DOI":"10.1074\/jbc.M002718200","volume":"275","author":"SA Cunningham","year":"2000","unstructured":"Cunningham SA, Arrate MP, Rodriguez JM, Bjercke RJ, Vanderslice P, Morris AP, et al. A novel protein with homology to the junctional adhesion molecule, Characterization of leukocyte interactions. J Biol Chem. 2000;275(44):34750\u20136.","journal-title":"J Biol Chem"},{"issue":"49","key":"1388_CR11","doi-asserted-by":"publisher","first-page":"45826","DOI":"10.1074\/jbc.M105972200","volume":"276","author":"MP Arrate","year":"2001","unstructured":"Arrate MP, Rodriguez JM, Tran TM, Brock TA, Cunningham SA. Cloning of human junctional adhesion molecule 3 (JAM3) and its identification as the JAM2 counter-receptor. J Biol Chem. 2001;276(49):45826\u201332.","journal-title":"J Biol Chem"},{"key":"1388_CR12","first-page":"91","volume":"251","author":"MA Aurrand-Lions","year":"2000","unstructured":"Aurrand-Lions MA, Duncan L, Du Pasquier L, Imhof BA. Cloning of JAM-2 and JAM-3: an emerging junctional adhesion molecular family? Curr Top Microbiol Immunol. 2000;251:91\u20138.","journal-title":"Curr Top Microbiol Immunol"},{"key":"1388_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/bs.ircmb.2018.05.013","volume":"343","author":"X Liu","year":"2019","unstructured":"Liu X, Fuentes EJ. Emerging themes in PDZ domain signaling: structure, function, and inhibition. Int Rev Cell Mol Biol. 2019;343:129\u2013218.","journal-title":"Int Rev Cell Mol Biol"},{"issue":"5","key":"1388_CR14","first-page":"2923","volume":"42","author":"X Li","year":"2018","unstructured":"Li X, Yin A, Zhang W, Zhao F, Lv J, Lv J, et al. Jam3 promotes migration and suppresses apoptosis of renal carcinoma cell lines. Int J Mol Med. 2018;42(5):2923\u20139.","journal-title":"Int J Mol Med"},{"issue":"5","key":"1388_CR15","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1172\/JCI93198","volume":"128","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xia F, Liu X, Yu Z, Xie L, Liu L, et al. JAM3 maintains leukemia-initiating cell self-renewal through LRP5\/AKT\/\u03b2-catenin\/CCND1 signaling. J Clin Investig. 2018;128(5):1737\u201351.","journal-title":"J Clin Investig"},{"key":"1388_CR16","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.2147\/CMAR.S189937","volume":"11","author":"D Zhou","year":"2019","unstructured":"Zhou D, Tang W, Zhang Y, An HX. JAM3 functions as a novel tumor suppressor and is inactivated by DNA methylation in colorectal cancer. Cancer Manag Res. 2019;11:2457\u201370.","journal-title":"Cancer Manag Res"},{"issue":"42","key":"1388_CR17","doi-asserted-by":"publisher","first-page":"44373","DOI":"10.18632\/oncotarget.6250","volume":"6","author":"A Yin","year":"2015","unstructured":"Yin A, Zhang Q, Kong X, Jia L, Yang Z, Meng L, et al. JAM3 methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix. Oncotarget. 2015;6(42):44373\u201387.","journal-title":"Oncotarget"},{"issue":"23","key":"1388_CR18","doi-asserted-by":"publisher","first-page":"6627","DOI":"10.1158\/0008-5472.CAN-17-1223","volume":"77","author":"M De Grandis","year":"2017","unstructured":"De Grandis M, Bardin F, Fauriat C, Zemmour C, El-Kaoutari A, Serg\u00e9 A, et al. JAM-C identifies Src family kinase-activated leukemia-initiating cells and predicts poor prognosis in acute myeloid leukemia. Can Res. 2017;77(23):6627\u201340.","journal-title":"Can Res"},{"issue":"2","key":"1388_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2019.11.029","volume":"158","author":"F Kastrinos","year":"2020","unstructured":"Kastrinos F, Samadder NJ, Burt RW. Use of family history and genetic testing to determine risk of colorectal cancer. Gastroenterology. 2020;158(2):389\u2013403.","journal-title":"Gastroenterology"},{"issue":"2","key":"1388_CR20","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1016\/S1470-2045(14)71016-2","volume":"16","author":"C Oliveira","year":"2015","unstructured":"Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015;16(2):e60-70.","journal-title":"Lancet Oncol"},{"key":"1388_CR21","doi-asserted-by":"publisher","first-page":"714071","DOI":"10.3389\/fgene.2021.714071","volume":"12","author":"C Zhu","year":"2021","unstructured":"Zhu C, Zhang M, Wang Q, Jen J, Liu B, Guo M. Intratumor epigenetic heterogeneity-a panel gene methylation study in thyroid cancer. Front Genet. 2021;12:714071.","journal-title":"Front Genet"},{"issue":"8","key":"1388_CR22","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S1470-2045(20)30219-9","volume":"21","author":"VR Blair","year":"2020","unstructured":"Blair VR, McLeod M, Carneiro F, Coit DG, D\u2019Addario JL, van Dieren JM, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21(8):e386\u201397.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1388_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2012.06.008","volume":"22","author":"JS You","year":"2012","unstructured":"You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012;22(1):9\u201320.","journal-title":"Cancer Cell"},{"issue":"9","key":"1388_CR24","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1038\/ajg.2009.300","volume":"104","author":"JS Wang","year":"2009","unstructured":"Wang JS, Guo M, Montgomery EA, Thompson RE, Cosby H, Hicks L, et al. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett\u2019s esophagus. Am J Gastroenterol. 2009;104(9):2153\u201360.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1388_CR25","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/ijc.22828","volume":"121","author":"M Guo","year":"2007","unstructured":"Guo M, House MG, Suzuki H, Ye Y, Brock MV, Lu F, et al. Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. Int J Cancer. 2007;121(6):1219\u201326.","journal-title":"Int J Cancer"},{"issue":"8","key":"1388_CR26","first-page":"2912","volume":"9","author":"MV Brock","year":"2003","unstructured":"Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003;9(8):2912\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1388_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1506597","volume":"374","author":"P Dalerba","year":"2016","unstructured":"Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, et al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N Engl J Med. 2016;374(3):211\u201322.","journal-title":"N Engl J Med"},{"issue":"7035","key":"1388_CR28","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321.","journal-title":"Nature"},{"issue":"7035","key":"1388_CR29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913\u20137.","journal-title":"Nature"},{"issue":"7","key":"1388_CR30","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1111\/cas.14917","volume":"112","author":"W Du","year":"2021","unstructured":"Du W, Gao A, Herman JG, Wang L, Zhang L, Jiao S, et al. Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer. Cancer Sci. 2021;112(7):2870\u201383.","journal-title":"Cancer Sci"},{"key":"1388_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40364-020-00224-1","volume":"8","author":"A Gao","year":"2020","unstructured":"Gao A, Guo M. Epigenetic based synthetic lethal strategies in human cancers. Biomark Res. 2020;8:44.","journal-title":"Biomark Res"},{"issue":"32","key":"1388_CR32","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1038\/sj.onc.1205620","volume":"21","author":"M van Hogerlinden","year":"2002","unstructured":"van Hogerlinden M, Auer G, Toftg\u00e5rd R. Inhibition of Rel\/Nuclear Factor-kappaB signaling in skin results in defective DNA damage-induced cell cycle arrest and Ha-ras- and p53-independent tumor development. Oncogene. 2002;21(32):4969\u201377.","journal-title":"Oncogene"},{"issue":"15","key":"1388_CR33","doi-asserted-by":"publisher","first-page":"8847","DOI":"10.1073\/pnas.95.15.8847","volume":"95","author":"A de La Coste","year":"1998","unstructured":"de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA. 1998;95(15):8847\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1388_CR34","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/hep.23538","volume":"51","author":"KN Nejak-Bowen","year":"2010","unstructured":"Nejak-Bowen KN, Thompson MD, Singh S, Bowen WC Jr, Dar MJ, Khillan J, et al. Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. Hepatology (Baltimore, MD). 2010;51(5):1603\u201313.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"6","key":"1388_CR35","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1101\/gad.1989311","volume":"25","author":"M Das","year":"2011","unstructured":"Das M, Garlick DS, Greiner DL, Davis RJ. The role of JNK in the development of hepatocellular carcinoma. Genes Dev. 2011;25(6):634\u201345.","journal-title":"Genes Dev"},{"issue":"4","key":"1388_CR36","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1053\/j.gastro.2008.01.016","volume":"134","author":"N Horiguchi","year":"2008","unstructured":"Horiguchi N, Wang L, Mukhopadhyay P, Park O, Jeong WI, Lafdil F, et al. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology. 2008;134(4):1148\u201358.","journal-title":"Gastroenterology"},{"issue":"2","key":"1388_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ccr.2012.01.001","volume":"21","author":"GS Feng","year":"2012","unstructured":"Feng GS. Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell. 2012;21(2):150\u20134.","journal-title":"Cancer Cell"},{"issue":"9","key":"1388_CR38","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1111\/cas.14565","volume":"111","author":"Y Hu","year":"2020","unstructured":"Hu Y, Guo M. Synthetic lethality strategies: Beyond BRCA1\/2 mutations in pancreatic cancer. Cancer Sci. 2020;111(9):3111\u201321.","journal-title":"Cancer Sci"},{"issue":"18","key":"1388_CR39","doi-asserted-by":"publisher","first-page":"9821","DOI":"10.1073\/pnas.93.18.9821","volume":"93","author":"JG Herman","year":"1996","unstructured":"Herman JG, Graff JR, My\u00f6h\u00e4nen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93(18):9821\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1388_CR40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jmoldx.2012.06.004","volume":"14","author":"Y Jia","year":"2012","unstructured":"Jia Y, Yang Y, Zhan Q, Brock MV, Zheng X, Yu Y, et al. Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer. J Mol Diagn JMD. 2012;14(6):577\u201385.","journal-title":"J Mol Diagn JMD"},{"issue":"12","key":"1388_CR41","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.4161\/epi.26781","volume":"8","author":"W Yan","year":"2013","unstructured":"Yan W, Wu K, Herman JG, Brock MV, Fuks F, Yang L, et al. Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. Epigenetics. 2013;8(12):1373\u201383.","journal-title":"Epigenetics"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-022-01388-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-022-01388-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-022-01388-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T10:50:22Z","timestamp":1678877422000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-022-01388-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1388"],"URL":"https:\/\/doi.org\/10.1186\/s13148-022-01388-3","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"6 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the Chinese PLA General Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We confirm that all authors agree with the submissions currently (and thereafter).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}